



AUSTRALIA
Biotech
Invest 2016

Connecting Capital with Innovation

www.australiabiotechinvest.com.au

26 - 27
October
2016

Host Industry Body Host State Partner Major Partner

AusBiotech
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

MELBOURNE
Victoria
Australia

100^{cs}
Just getting started

Melbourne Convention
Centre, Victoria, Australia

Paranta Biosciences

Paranta Biosciences is an Australian based, biopharmaceutical company focused on the development and commercialisation of PB01, a recombinant form of human follistatin-288. PB01 has anti-inflammatory & anti-fibrotic actions. Inhaled PB01 is in clinical development for treatment of neutrophilic lung diseases, including cystic fibrosis. Phase 1 clinical trials are currently underway. Intravenously administered PB01 has demonstrated action in preclinical studies as a sensitising agent in combination with platinum based chemotherapy. Paranta is seeking suitable partners to progress with the development of PB01 in respiratory and oncology indications.